Semax Peptide: A Research Overview of the ACTH Analogue
Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences from the N-terminal-adjacent region of adrenocorticotropic hormone (ACTH). It is among the better-documented neuroactive peptides in the Russian-language literature and has been studied in rodent models of learning, cerebral ischemia and stress, with a smaller number of in vitro and gene-expression studies. This overview summarises what the published literature reports about its structure, its proposed mechanisms, and the preclinical models in which it has been examined, together with practical notes on laboratory handling.
Structure and Chemical Identity
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), a molecular formula of C37H51N9O10S, a molecular weight of approximately 813.9 g/mol, and the CAS registry number 80714-61-0. The first four residues, Met-Glu-His-Phe, correspond to ACTH(4–7). The C-terminal Pro-Gly-Pro tripeptide was appended by design, because proline-rich termini are generally more resistant to exopeptidase degradation than the unmodified ACTH fragment, which is cleared very quickly in biological matrices.
A defining structural feature of Semax is what it lacks. The ACTH(4–10) region that inspired it is associated in older literature with behavioural and memory-related effects in rodents, whereas the full ACTH(1–24) sequence is required for adrenocortical stimulation. Semax does not contain the His-Phe-Arg-Trp motif in its entirety and has been described as lacking corticotropic activity, which is part of why it has been used as a probe for non-endocrine melanocortin-family biology. Researchers should note, however, that the exact receptor pharmacology of the compound remains less settled than its structure, as discussed below.
Proposed Mechanisms
Melanocortin-family and receptor-binding questions
Because Semax is derived from ACTH, early work focused on whether it acts through melanocortin receptors. Radioligand-binding experiments using labelled Semax and rat brain membrane preparations reported specific, saturable binding to plasma membranes from forebrain basal nuclei, and the same work examined the peptide's biodegradation in that preparation. The identity of the binding site, however, has not been conclusively assigned, and commentary in the field notes that reports on its activity at individual melanocortin receptor subtypes have been inconsistent. A cautious reading is that Semax interacts with brain membrane targets in vitro, but that its receptor mechanism is an open question rather than an established one.
Neurotrophin signalling
The most frequently cited mechanistic observation concerns brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (trkB). Dolotov and colleagues (Brain Research, 2006) reported that a single intranasal application of Semax at 50 µg/kg in rats was followed by a maximal 1.4-fold increase in hippocampal BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and approximately 3-fold and 2-fold increases in exon III BDNF and trkB mRNA, respectively. In the same study, treated animals showed more conditioned avoidance reactions in a learning paradigm, which the authors interpreted as consistent with modulation of hippocampal BDNF/trkB signalling. Related work from the same broader research community examined neurotrophin gene expression in other rat brain regions after Semax exposure, and reported region-dependent changes in NGF and BDNF transcripts rather than a uniform effect.
These are observations in rodents following a specific route and dose. They describe changes in molecular markers and a behavioural readout in an animal learning task and should not be generalised beyond that experimental context.
Gene-Expression Studies in Ischemia Models
A second major strand of research uses genome-wide transcriptional profiling in rat models of focal cerebral ischemia. Medvedeva and colleagues (BMC Genomics, 2014) examined rats subjected to permanent middle cerebral artery occlusion (pMCAO) and treated with Semax at 100 µg/kg intraperitoneally at 15 minutes, 1, 4 and 8 hours after occlusion. Using a 1.5-fold cutoff, they reported 96 genes with altered expression at 3 hours and 68 genes at 24 hours. The peptide predominantly increased expression of genes related to the immune system; at 24 hours, immune-response genes made up more than half of all altered genes, with immunoglobulin and chemokine genes among the most prominent. Twenty-four vascular-process genes were altered at 3 hours and 12 at 24 hours, spanning functions such as endothelial development, smooth muscle migration and vasculogenesis.
A follow-up paper from overlapping authors (Molecular Genetics and Genomics, 2017) analysed an ACTH(4–7)-derived Semax regimen and again reported effects on immune-response gene expression during ischemic brain injury in rats. Taken together, these studies characterise Semax as a modulator of transcriptional programmes in injured rodent brain tissue. They do not by themselves establish the causal pathway between a given transcript change and any functional outcome, and the authors of such transcriptomic work typically frame them as hypothesis-generating.
Pharmacokinetic and Stability Considerations in Research Design
Short peptides of this size present characteristic analytical challenges. Linear heptapeptides are generally subject to rapid proteolysis in tissue homogenates and biological fluids, and the binding study noted above explicitly examined Semax biodegradation alongside membrane binding, reflecting that stability is a central variable in interpreting any bioassay. In practical terms, investigators who compare outcomes between studies need to account for the route of delivery, the vehicle, the sampling interval, and whether intact peptide or its fragments were quantified. The Pro-Gly-Pro tripeptide is itself a known fragment of collagen turnover and has been examined separately in the Russian literature, including in combination with Semax in transcriptional studies of ischemic rat brain, which complicates attribution when the intact parent and its degradation products are both present.
For in vitro work, the same considerations apply to culture media. Serum-containing media contain peptidases that can shorten the effective exposure window, so many protocols either use serum-free conditions for the exposure period or verify peptide persistence by LC-MS at the experimental endpoint. Including a scrambled-sequence or truncated-peptide control, such as the Pro-Gly-Pro tripeptide alone, helps separate sequence-specific observations from non-specific peptide effects.
Stress and Calcium-Signalling Research
Melanocortin derivatives, including Semax, have also been examined in rat acute-stress paradigms, where investigators measured hippocampal gene-expression patterns after stress exposure and compared peptide-treated with untreated animals (International Journal of Molecular Sciences, 2021). More recently, a 2025 paper in Bulletin of Experimental Biology and Medicine reported on the effect of Semax on intracellular calcium dynamics in rat brain neurons, extending the work from transcript-level observations toward cellular signalling. Both lines of work are early-stage and, like most of the Semax literature, derive from a relatively small number of research groups.
What the Evidence Does and Does Not Show
Several limitations are worth stating plainly when planning experiments around this compound. First, a large share of the primary literature originates from a few laboratories, and independent replication in other institutions is limited. Second, doses and routes in the cited rat studies (intranasal and intraperitoneal) are specific to the models used and are not interchangeable. Third, effects on mRNA abundance do not always translate to proportional protein or functional changes. Finally, the receptor-level mechanism is unresolved. For these reasons, Semax is best treated as a tool compound for studying neurotrophin signalling and injury-associated transcription in animal and cell systems, not as a compound with established effects in any other setting.
Laboratory Handling Notes
Semax is typically supplied as a lyophilised powder. The sequence contains a methionine residue, which is susceptible to oxidation, and a histidine residue that can influence solubility and metal-ion interactions. Standard practice for peptides with these features includes storing lyophilised material at −20°C or colder, protected from light and moisture, and allowing the vial to equilibrate to room temperature before opening to limit condensation. After reconstitution in a suitable sterile diluent, solutions are generally kept at 2–8°C, used within a limited period, and aliquoted to avoid repeated freeze–thaw cycles, which can promote aggregation and oxidation. Using low-adsorption plasticware and degassed or nitrogen-flushed solvents can further reduce methionine oxidation in sensitive assays.
Identity and purity should be confirmed independently for any peptide used in quantitative work. Batch-level analytical data, including HPLC purity and mass confirmation of the expected ~813.9 Da species, can be reviewed on the Lab Results page. Because methionine oxidation produces a +16 Da species that can co-elute or appear as a shoulder in chromatograms, mass spectrometry is a useful complement to HPLC for this particular sequence; see HPLC vs Mass Spec: What Peptide Purity Really Means.
Summary
Semax is a seven-residue ACTH-derived peptide whose published research centres on hippocampal BDNF/trkB signalling after intranasal administration in rats and on genome-wide transcriptional changes in rat ischemia models, with emerging work on stress responses and neuronal calcium dynamics. The structural chemistry is well defined; the receptor mechanism is not. Researchers evaluating the literature should weigh its concentration in a small number of groups and the model-specific nature of the dosing and endpoints.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.